Introduction
============

When performing ovarian stimulation for *in vitro* fertilization (IVF), acquiring an appropriate number of oocytes is an important prerequisite for a successful pregnancy. Several previous studies have shown that obtaining 8--14 oocytes is optimal for the likelihood of a successful pregnancy, while avoiding the risk of ovarian hyperstimulation syndrome (OHSS) \[[@B1][@B2][@B3]\]. In women who are expected to be normal responders and are undergoing IVF for the first time, clinicians usually choose 150 IU or 225 IU, and sometimes 300 IU, of exogenous follicle-stimulating hormone (FSH). This empiric choice is commonly based on a comprehensive consideration of the woman\'s age and several ovarian reserve tests, such as serum levels of anti-Müllerian hormone (AMH) or FSH and the antral follicle count (AFC) \[[@B4][@B5][@B6][@B7][@B8][@B9]\]. The empiric choice of the FSH starting dose can sometimes unexpectedly result in a nonoptimal ovarian response.

La Marca et al. \[[@B10]\] proposed a nomogram for individualization of the FSH starting dose. The nomogram proposed by the authors allows the FSH starting dose to be chosen by a combination of female age and serum AMH or FSH. This nomogram was originally developed with the goal of maximizing the likelihood that women who are expected normal responders would obtain eight oocytes. However, a recent study has shown that the optimal number of oocytes, in terms of the live birth rate, was 13 \[[@B11]\]. In addition, it has been suggested that aiming to collect between 18 and 20 oocytes is the most favorable in terms of the cumulative live birth rate \[[@B12]\].

Many clinicians feel that the FSH dose suggested by the nomogram may be lower than expected empirically. An empiric choice of the FSH starting dose can sometimes result in hyper-response; however, if up to 10 oocytes are obtained, blastocyst transfer can be considered to maximize the implantation rate and to decrease the likelihood of a multi-fetal pregnancy. Otherwise, surplus embryos can be frozen and be used in subsequent cycles, maximizing the pregnancy rate.

La Marca et al. \[[@B10]\] developed their nomogram without considering the pregnancy rate. Although the nomogram was validated by a randomized study, that study still did not consider the pregnancy rate \[[@B13]\]. For this reason, their nomogram needs to be further validated. To evaluate the appropriateness of their nomogram, we retrospectively analyzed 117 consecutive first IVF cycles performed in expected normal responders. The FSH starting dose was determined by empiric choice, but it was incidentally concordant with the dose specified by La Marca\'s nomogram in 34 cycles (the concordant group). The FSH starting dose was not concordant with the dose specified by La Marca\'s nomogram in the remaining 83 cycles (the discordant group). Cycle outcomes and the pregnancy rate were compared between the two groups.

Methods
=======

1. Subjects
-----------

A retrospective study was performed under approval by the Institutional Review Board (IRB No. B-1805/471-101). A total of 117 infertile women who underwent their first IVF cycles from 2011 to 2017 at Seoul National University Bundang Hospital were selected. The selection criteria were the same as in La Marca\'s study: (1) first IVF or intracytoplasmic sperm injection (ICSI) cycle, (2) female age ≤40 years, (3) regular menstrual cycle of 25--35 days, (4) continuation of the initial starting FSH dose for the first 5 days, (5) serum AMH 1.0--4.0 ng/mL, (6) basal serum FSH ≤15 IU/L, and (7) normal uterine cavity. The exclusion criteria were as follows: (1) polycystic ovarian syndrome, (2) previous ovarian surgery, (3) stage III--IV endometriosis, (4) history of oral contraceptives in the previous 3 months, (5) any proven metabolic or endocrine diseases, and (6) frozen embryo transfer.

2. IVF protocol
---------------

In all cases, recombinant FSH (Gonal F; Merck Serono, Darmstadt, Germany) and a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol were used. The starting dose of recombinant FSH was empirically determined by clinicians (150, 225, or 300 IU). The GnRH antagonist (Cetrotide, Merck Serono) was administrated daily when the leading follicle reached 14 mm in diameter. When the leading follicles reached 19 mm in diameter, ovulation was triggered by injecting 250 µg of recombinant human chorionic gonadotropin (Ovidrel, Merck Serono). The oocyte was retrieved 35--36 hours later. Embryo transfer was performed 3 or 5 days after oocyte retrieval. The luteal phase was supported either by daily progesterone injection or vaginal gel (Crinone, Merck Serono). A serum human chorionic gonadotropin test was performed 14 days after oocyte retrieval. The implantation rate was defined as the number of gestational sacs observed on ultrasonography at 6 weeks of pregnancy divided by the number of embryos transferred. Clinical pregnancy was confirmed by the visualization of at least 1 gestational sac. Ongoing pregnancy was defined when the pregnancy had completed ≥20 weeks of gestation. Cleavage-stage grade A embryos were identified on day 3 according to the following morphological criteria: equal-sized blastomeres and no fragments, with no apparent morphologic abnormalities.

3. Concordance of FSH starting dose
-----------------------------------

In the 117 IVF cycles, the proposed FSH starting dose was determined using female age and serum AMH or basal FSH as indicated in La Marca\'s nomogram. In our hospital, the method of the serum AMH assay changed during the study period (2011 to 2017). The Immunotech (IOT) assay was used until August 2012, the original Gen II kit was used from September 2012 to July 2013, and then the revised Gen II kit was used from August 2013 to July 2016. Since August 2016, we have used a fully automated AMH assay system based on the revised Gen II kit. To correct for these changes, we used the formulas reported in previous studies. The revised Gen II assay results were converted to the original Gen II assay values using the following formula: revised protocol AMH value=0.929+1.658×(original AMH value)−0.006×(original AMH value)^2^ \[[@B14]\]. Subsequently, the original Gen II assay results were converted to the IOT assay values by the following equation: Gen II AMH value=1.353×(IOT AMH value)+0.051 \[[@B15]\].

If the dose that was administered was exactly the same as the dose specified by the nomogram, cycles were assigned to the concordant group (34 cycles). If not, they were assigned to the discordant group (83 cycles). If the proposed dose was over 225 IU, and the administered dose was 300 IU, the cycle was assigned to the concordant group. If the proposed dose was over 225 IU and the administered dose was 225 or 150 IU, the cycle was assigned to the discordant group.

4. Outcomes and statistical analysis
------------------------------------

In the present study, optimal ovarian response was defined as between 8 and 14 total retrieved oocytes. Hypo-response was defined as fewer than eight retrieved oocytes, and hyper-response was defined as more than 14 retrieved oocytes. All statistical analyses were performed using IBM SPSS ver. 23.0 (IBM Corp., Armonk, NY, USA). Most of the numerical data did not show a normal distribution; thus, the data are presented as median and interquartile range. The nonparametric Mann-Whitney *U*-test was used to compare mean values between groups. The chi-square test or the Fisher exact test was used to compare proportions. The results were considered statistically significant when the *p*-value was \<0.05.

Results
=======

The clinical characteristics of both groups are shown in [Table 1](#T1){ref-type="table"}. Women\'s age, basal serum FSH levels, and serum AMH levels were all similar between the two groups. The stimulation outcomes are summarized in [Table 2](#T2){ref-type="table"}. The most frequent actual starting dose was 225 IU (95 cycles) and 28.4% of those cycles were in the concordant group. In 13 cycles, the starting dose of FSH was 150 IU, and most of those cycles were in the discordant group. In nine cycles, 300 IU was used as the starting dose of FSH, and 66.7% of those cycles were in the concordant group. In the concordant group, the FSH dose was not increased on day 6 of stimulation in any patients, but it was decreased in two women on day 6 of stimulation ([Table 2](#T2){ref-type="table"}). In the discordant group, the FSH dose was increased starting on day 6 of stimulation in one woman and was decreased on day 6 of stimulation in seven women. Overall, 91.5% of all cycles maintained the FSH starting dose throughout the entire period of ovarian stimulation.

The total FSH dose administered and the serum estradiol level on triggering day were similar between the concordant and discordant groups ([Table 2](#T2){ref-type="table"}). The number of total or mature oocytes retrieved, the optimal ovarian response rate, and the rate of hypo-response or hyper-response were all similar between the concordant and discordant groups ([Table 2](#T2){ref-type="table"}).

Embryo transfer and pregnancy outcomes are presented in [Table 3](#T3){ref-type="table"}. Embryo transfer was cancelled in 15 cycles. A freeze-all policy was implemented due to OHSS risk in two women in the discordant group (serum estradiol levels on triggering day of 3,174 pg/mL and 2,924 pg/mL with a total number of 15 and 12 oocytes, respectively). Only one woman (in the discordant group) was hospitalized due to the development of moderate OHSS. There were no significant differences in the implantation rate, clinical pregnancy rate, ongoing pregnancy rate, miscarriage rate, or live birth rate ([Table 3](#T3){ref-type="table"}).

Discussion
==========

In this retrospective study, we observed no differences in the optimal ovarian response, acquisition of high-quality embryos, or resultant pregnancy rates according to the concordance of the FSH dose with that calculated by La Marca\'s nomogram. Efforts have been made to tailor or individualize the FSH starting dose to avoid unfavorable excessive or suboptimal ovarian response. Several nomograms based on the AFC have been proposed to determine individualized FSH starting doses \[[@B4][@B5][@B16][@B17][@B18]\]. Those researchers argued that determining the FSH starting dose by those nomograms and subsequent dose adjustment could reduce cycle cancellation due to inadequate ovarian response. However, not enough evidence has emerged to support those nomograms based on the AFC. Individualized FSH dosing did not show any significant benefit when considering the cost-effectiveness of conventional dosing based on 150 IU \[[@B17][@B19]\].

La Marca et al. \[[@B10]\] proposed a nomogram based on women\'s age and serum AMH and/or FSH levels. They proposed that using this nomogram would allow an optimal number of oocytes to be obtained in 29.7% of women even though an FSH dose less than 225 IU was used as the starting dose. Furthermore, it was expected that this would increase the live birth rate and reduce the overall treatment cost. In order to validate La Marca\'s nomogram, that research group conducted two consecutive studies. First, Papaleo et al. \[[@B20]\] retrospectively analyzed data obtained from two separate institutions. However, they included poor and high responders along with normal responders. La Marca et al. \[[@B10]\] developed their nomogram for normal responders only. Among the 255 women who obtained a suboptimal number of oocytes (\<8 or \>14), 18.8% used an inappropriate FSH dose. They did not present the total number of patients who received each FSH dose or pregnancy outcomes.

Second, Allegra et al. \[[@B13]\] performed a randomized trial to validate the nomogram. They only included expected normal responders. In the patients in whom the FSH starting dose was chosen empirically, it was 150 IU for women ≤35 years and 225 IU for women \>35 years. They showed a lower rate of optimal ovarian response in the empiric choice group versus the nomogram-based choice group (42.4% vs. 63.0%). However, the FSH starting dose was 150 IU in 55% of the women in the empiric choice group, meaning that a suboptimal ovarian response would be expected in that group.

In the present retrospective study, the FSH starting dose was 225 IU in 81.9% of the women in the discordant dose group. In the study by Papaleo et al. \[[@B20]\], the proportion of women who used 225 IU as the starting dose of FSH in the discordant dose group was similar to our study. In the study by Allegra et al. \[[@B13]\], most women in the empiric choice group used a lower-than-usual dose.

In addition, both of the above studies had limitations in the AMH assay method. La Marca et al. \[[@B10]\] used the IOT assay, although both validation studies used revised Gen II assay kit values. AMH concentrations using the Gen II assay tend to be higher than those obtained using the IOT, and the revised GEN II results have been reported to be higher than the original GEN II values \[[@B14][@B15]\]. Therefore, performing a validation study using AMH results that did not compensate for these differences could have been a significant source of bias in the study results. In this study, AMH values were modified to reflect these differences, which is an advantage over previous studies.

In fact, La Marca\'s nomogram was developed with the basic goal of avoiding ovarian hyper-response in normal responders. However, in the present retrospective study, the hyper-response rate was similar between the concordant and discordant dose groups although the majority of women received 225 IU. Surplus embryos to be cryopreserved were obtained in seven of the 34 cycles in the concordant group (20.6%) and in 15 of the 83 cycles in the discordant group (18.1%). The overall ovarian response was similar between the concordant and discordant dose groups, as was the resultant pregnancy rate.

In normal responders, avoidance of ovarian hyper-response may be unnecessary. If up to 10 oocytes are obtained, blastocyst transfer can be considered to maximize the implantation rate and to reduce the likelihood of a multi-fetal pregnancy. Otherwise, surplus embryos can be frozen for use in subsequent thawed cycles, thereby maximizing the pregnancy rate \[[@B21]\].

Therefore, an FSH starting dose of 225 IU would be a good option when considering the cumulative pregnancy rate through consecutive frozen embryo transfer \[[@B22]\]. Moreover, many clinicians increase the FSH starting dose in the second IVF cycle in women who use 150 IU in the first cycle and do not become pregnant. This strategy may result in a more favorable ovarian response and pregnancy outcomes \[[@B23]\]. Many clinicians do not choose 300 IU as an FSH starting dose in normal responders, because severe OHSS should be avoided \[[@B24]\].

This study had some limitations. First, this was not a prospective validation study. Second, women who used a different dose during the first 5 days were excluded. More variable FSH dose schedules exist, such as 225 IU in the first 3 days, with changes thereafter according to women\'s response. In conclusion, the use of La Marca\'s nomogram seems to have no significant advantages over the conventional empiric choice in terms of the number of oocytes retrieved or the pregnancy outcomes when applied to expected normal responders in IVF/ICSI cycles. Further prospective studies are needed to clarify the advantages of individualized FSH dosing.
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###### Clinical characteristics between the two groups
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Values are presented as median (interquartile range) or number (%).

FSH, follicle-stimulating hormone; AMH, anti-Müllerian hormone.

###### Ovarian stimulation outcomes between the two groups
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Values are presented as number (%) or median (interquartile range).

FSH, follicle-stimulating hormone.

###### Embryo transfer and pregnancy outcomes between the two groups
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Values are presented as median (interquartile range) or number (%) unless otherwise indicated.

OHSS, ovarian hyperstimulation syndrome.

^a)^Seven cycles; ^b)^Fifteen cycles.
